Coherus Announces Special Cyber Dividend of CVRs
Coherus Oncology (CHRS) will distribute a special dividend of contingent value rights to stockholders, entitling them to the net proceeds from the sale of remaining legacy biosimilar assets. This restructuring measure underscores the company’s strategic pivot to focus exclusively on innovative immuno-oncology therapies.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day